Municipal Employees Retirement System of Michigan grew its holdings in Eli Lilly and Co (NYSE:LLY) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 59,820 shares of the company’s stock after purchasing an additional 2,670 shares during the quarter. Municipal Employees Retirement System of Michigan’s holdings in Eli Lilly and were worth $5,052,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of LLY. Avestar Capital LLC bought a new stake in shares of Eli Lilly and during the fourth quarter worth $100,000. Gradient Investments LLC bought a new stake in shares of Eli Lilly and during the fourth quarter worth $103,000. MPS Loria Financial Planners LLC bought a new stake in shares of Eli Lilly and during the second quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new stake in shares of Eli Lilly and during the second quarter worth $129,000. Finally, Front Row Advisors LLC bought a new stake in shares of Eli Lilly and during the fourth quarter worth $137,000. 77.58% of the stock is currently owned by institutional investors.
In related news, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares of the company’s stock, valued at $334,901.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald A. Zakrowski sold 860 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total value of $65,790.00. The disclosure for this sale can be found here. Insiders have sold 12,261 shares of company stock valued at $987,485 over the last three months. Insiders own 0.20% of the company’s stock.
Eli Lilly and Co (LLY) opened at $78.75 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $85,993.48, a PE ratio of -393.73, a PEG ratio of 1.46 and a beta of 0.28. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. Eli Lilly and’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 earnings per share. research analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
A number of research firms recently commented on LLY. TheStreet downgraded Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Bank of America dropped their price objective on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. JPMorgan Chase & Co. set a $105.00 price objective on Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. Jefferies Group set a $93.00 price objective on Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. Finally, Credit Suisse Group reiterated a “hold” rating and issued a $80.00 price objective on shares of Eli Lilly and in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $93.47.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.